Patents Assigned to Nammi Therapeutics, Inc.
  • Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
    Patent number: 12162958
    Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
    Type: Grant
    Filed: September 14, 2023
    Date of Patent: December 10, 2024
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Sherie Morrison, Alex Vasuthasawat, Kham Trinh, George Ayoub
  • Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
    Patent number: 12059470
    Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: May 8, 2023
    Date of Patent: August 13, 2024
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
    Patent number: 11896646
    Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: February 13, 2024
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
    Patent number: 11833209
    Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: December 5, 2023
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
    Patent number: 11801304
    Abstract: Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: October 31, 2023
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
    Patent number: 11744874
    Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: September 5, 2023
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
  • Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
    Patent number: 11679141
    Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: June 20, 2023
    Assignee: Nammi Therapeutics, Inc.
    Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie